LUNG Pulmonx Corp
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1127537 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-3.2%
TTM net income YoY25.0%
TTM EPS YoY28.4%
Revenue 3-yr CAGR11.1%
Net income 3-yr CAGR—
Margins
Gross margin77.4%
Operating margin-44.4%
Net margin-47.9%
FCF margin-28.8%
EBITDA margin-43.4%
Returns
ROE-90.3%
ROA-34.2%
ROIC (approx.)-155.9%
Asset turnover0.71x
Leverage & solvency
Liabilities / assets69.0%
Debt / equity1.11x
Current ratio4.05x
Interest coverage-9.39x
Cash quality & payout
Operating cash flow / net income0.60x
Accruals ratio-13.7%
Payout ratio—
Capex / revenue0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $90.50M | $83.79M |
| Cost of revenue | $23.36M | $21.79M |
| Gross profit | $67.14M | $62.00M |
| R&D expense | $19.49M | $17.57M |
| SG&A expense | $101.31M | $102.14M |
| Operating income | -$53.66M | -$57.70M |
| Interest expense | $3.15M | $3.51M |
| Pretax income | -$53.38M | -$55.89M |
| Income tax | $626,000 | $500,000 |
| Net income | -$54.00M | -$56.39M |
| EBITDA | -$52.56M | -$56.60M |
| EPS (basic) | -1.33 | -1.44 |
| EPS (diluted) | -1.33 | -1.44 |
| Weighted avg. shares (diluted) | 40.69M | 39.11M |
| Balance sheet | ||
| Cash & equivalents | $69.75M | $71.16M |
| Receivables | $12.07M | $13.12M |
| Inventory | $15.85M | $16.91M |
| Current assets | $101.68M | $136.25M |
| PP&E, net | $2.22M | $2.91M |
| Goodwill | $2.33M | $2.33M |
| Intangibles | — | $0 |
| Total assets | $129.29M | $162.85M |
| Current liabilities | $20.06M | $24.44M |
| Short-term debt | $106,000 | $3.18M |
| Long-term debt | $36.99M | $34.00M |
| Total debt | $37.09M | $37.18M |
| Total liabilities | $75.17M | $77.04M |
| Shareholders' equity | $54.12M | $85.81M |
| Net debt | -$32.66M | -$33.98M |
| Shares outstanding | 41.67M | 39.79M |
| Cash flow statement | ||
| Operating cash flow | -$32.38M | -$31.54M |
| Capital expenditure | $452,000 | $1.45M |
| Free cash flow | -$32.83M | -$32.98M |
| Investing cash flow | $30.48M | $17.48M |
| Financing cash flow | $833,000 | $1.36M |
| Depreciation & amortization | $1.10M | $1.10M |
| Stock-based compensation | $21.23M | $22.95M |
Free plan shows the latest 2 periods; Pro shows all 8 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.